Status:
COMPLETED
Efficacy and Safety of 28 or 56 Day Treatment for Pseudomonas Aeruginosa in Children With Cystic Fibrosis
Lead Sponsor:
Novartis
Conditions:
Cystic Fibrosis
Eligibility:
All Genders
6+ years
Phase:
PHASE3
Brief Summary
This study assessed time to recurrence of infection with Pseudomonas aeruginosa following treatment of the initial infection with tobramycin nebuliser solution. The safety profile of the initial tobra...
Detailed Description
This was a multi-center, open-label, two-arm, randomized study. All patients diagnosed with CF and who fulfilled the criteria for early infection with P. aeruginosa initially received tobramycin 300 m...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Male or female patients ≥ 6 months old
- Diagnosis of cystic fibrosis (CF) based upon the following historical criteria performed prior to study participation:
- confirmed sweat chloride \> 60 mEq/L by quantitative pilocarpine iontophoresis (at least 2 tests), OR
- genotype with two identifiable mutations consistent with CF.
- First or early lower respiratory tract infection with Pseudomonas (P.) aeruginosa documented by either of the following:
- first infection defined by the first P. aeruginosa isolated from sputum or deep throat cough swab culture, OR
- P. aeruginosa from sputum or deep throat cough swab culture following at least 1 year of negative cultures (documented with at least 4 negative cultures during this year and no positive cultures) and no anti-pseudomonal treatment during this 1-year period, OR
- P. aeruginosa from sputum or deep throat cough swab culture following at least 2 years of negative cultures (documented with at least 2 negative cultures per year and no positive cultures) and no anti-pseudomonal treatment during this 2-year period.
- Written informed consent by the patient and/or parent/legal guardian according to local country regulations.
- Exclusion criteria:
- History of aminoglycoside hypersensitivity or adverse reaction to inhaled aminoglycoside.
- Signs and symptoms of acute pulmonary disease, eg, pneumonia, pneumothorax.
- Administration of any investigational drug within 30 days prior to enrollment.
- Administration of loop diuretics within 7 days prior to study drug administration.
- Personal/family history of abnormal hearing, other than typical hearing loss associated with the aging process.
- Abnormal result from an audiology testing (defined as either a unilateral pure-tone audiometry test showing a threshold elevation \> 20 decibels \[dB\] at any frequency across the frequency range 0.25-8 kHz or the absence of emission at the evoked otoacoustic emission test).
- Positive urine pregnancy test at Day 1 (Baseline) for all female patients who have reached menarche.
- Use of macrolide antibiotics as a maintenance therapy for 12 or more days during the 28 days prior to Baseline.
- Antibody titers ≥ 1000 for any of the 3 P. aeruginosa exoenzymes: Exotoxin A, alkaline protease, or elastase (status to be determined between Baseline and Day 28).
Exclusion
Key Trial Info
Start Date :
November 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2008
Estimated Enrollment :
123 Patients enrolled
Trial Details
Trial ID
NCT00391976
Start Date
November 1 2003
End Date
January 1 2008
Last Update
August 29 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.